Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
This study has been completed.
Sponsor:
ChemGenex Pharmaceuticals
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( ChemGenex Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00114959
First received: June 20, 2005
Last updated: May 16, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | March 2009 |
| Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
| Certification or Request for Extension to Delay Results Received: | May 3, 2012 |